118 related articles for article (PubMed ID: 31571043)
1. Comparisons of
Lee I; Byun BH; Lim I; Kim BI; Choi CW; Kim KM; Shin DY; Kang HJ; Lim SM
Ann Nucl Med; 2019 Dec; 33(12):881-890. PubMed ID: 31571043
[TBL] [Abstract][Full Text] [Related]
2. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.
Cazaentre T; Morschhauser F; Vermandel M; Betrouni N; Prangère T; Steinling M; Huglo D
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):494-504. PubMed ID: 19820933
[TBL] [Abstract][Full Text] [Related]
3. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
McQuillan AD; Macdonald WB; Turner JH
Leuk Lymphoma; 2015 May; 56(5):1271-7. PubMed ID: 25065701
[TBL] [Abstract][Full Text] [Related]
5. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT and Dosimetric Studies of
Løndalen A; Blakkisrud J; Revheim ME; Dahle J; Kolstad A; Stokke C
Mol Imaging Biol; 2022 Oct; 24(5):807-817. PubMed ID: 35486292
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
8. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab.
Lim I; Park JY; Kang HJ; Hwang JP; Lee SS; Kim KM; Choi TH; Yang SH; Kim BI; Choi CW; Lim SM
Acta Haematol; 2013; 130(2):74-82. PubMed ID: 23548464
[TBL] [Abstract][Full Text] [Related]
10. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
Visser OJ; Perk LR; Zijlstra JM; van Dongen GA; Huijgens PC; van de Loosdrecht AA
BioDrugs; 2006; 20(4):201-7. PubMed ID: 16831019
[TBL] [Abstract][Full Text] [Related]
12. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma.
Kang HJ; Lee SS; Byun BH; Kim KM; Lim I; Choi CW; Suh C; Kim WS; Nam SH; Lee SI; Eom HS; Shin DY; Lim SM
Cancer Chemother Pharmacol; 2013 Apr; 71(4):945-53. PubMed ID: 23370662
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
14. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after involved-field radiation therapy (IFRT) with or without rituximab in patients with early-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT and PET.
Lukens JN; Nasta SD; Fram B; Glatstein E; Plastaras JP
Am J Clin Oncol; 2014 Feb; 37(1):35-40. PubMed ID: 22992623
[TBL] [Abstract][Full Text] [Related]
16. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
18. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
19. Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma.
Grgic A; Nestle U; Scheidhauer K; Puskas C; Ballek E; Hohloch K; Schubert J; König J; Pinkert J; Truemper L; Hellwig D; Kirsch CM
Nuklearmedizin; 2011; 50(1):39-47. PubMed ID: 21057722
[TBL] [Abstract][Full Text] [Related]
20. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
